Zentalis Pharmaceuticals Shares Updated Data on Azenosertib
Zentalis Pharmaceuticals, Inc. is making significant strides with its innovative treatment, azenosertib, in the fight against platinum-resistant ovarian cancer (PROC). Recent data presented at a major oncology meeting revealed compelling results that highlight the potential of this therapy in improving patient outcomes. In a single-arm Phase 2 DENALI Part 1b clinical trial, azenosertib has shown a median duration of response (mDOR) of 6.3 months, with an objective response rate (ORR) of approximately 35% among patients evaluated for their response.
Details of the DENALI Part 1b Clinical Trial
The DENALI Part 1b clinical trial focused on administering azenosertib alone in patients suffering from PROC. This trial evaluated 102 patients using a dosing schedule of 400 mg once daily, with an intermittent schedule of five days on and two days off. The data cutoff, noted as January 13, 2025, indicated promising results in patients with Cyclin E1+ PROC tumors. Specifically, those who were deemed response-evaluable had an ORR of 34.9%, translating to 15 out of 43 patients showing a positive response.
Response Evaluation and Biomarkers
Moreover, in the overall patient group who received at least one dose of azenosertib, the ORR was reported at 31.3%. The safety profile observed remains consistent with earlier presentations, showing gastrointestinal toxicities and fatigue as the most common adverse effects experienced by patients. This consistency underscores the viability of azenosertib as a treatment choice.
Importance of Cyclin E1 as a Predictive Biomarker
The ongoing studies also pointed to Cyclin E1 as a crucial biomarker for predicting responses to the treatment. Zentalis Pharmaceuticals estimates that about half of PROC patients overexpress this protein, making it a valuable target for identifying candidates who may benefit from azenosertib. This is particularly important, given the challenging nature of treating platinum-resistant ovarian cancers, which are known to exhibit poorer outcomes post-chemotherapy.
The Future of Azenosertib in Clinical Trials
Zentalis is gearing up for the next phase of its clinical exploration by planning to initiate enrollment for Part 2 of the DENALI trial within the first half of 2025. If the results from Part 2 are favorable, there is a strong potential for accelerated approval through the FDA, which would allow for earlier access to the treatment for patients in need.
Combination Therapy Potential
In addition to the monotherapy insights, Zentalis Pharmaceuticals is presenting preclinical data on the combination of azenosertib with microtubule inhibitor-based antibody-drug conjugates (ADCs). These preclinical results illustrate enhanced antitumor effects, indicating that azenosertib may serve effectively alongside other therapies, potentially improving treatment responses for various solid tumors.
About Zentalis Pharmaceuticals and Its Vision
Zentalis Pharmaceuticals is dedicated to pioneering innovative solutions in the space of oncology, particularly with its lead candidate, azenosertib. This drug is currently under evaluation in clinical trials targeting not only ovarian cancer but also other tumor types where unmet medical needs exist. The commitment of Zentalis to develop impactful treatments for patients living with complex cancers shines through its extensive research efforts and strategic collaborations.
Frequently Asked Questions
What is azenosertib?
Azenosertib is an oral WEE1 inhibitor that is being studied for its application in treating various cancers, including platinum-resistant ovarian cancer.
What were the results presented at the SGO meeting?
The presentation highlighted an updated median duration of response of 6.3 months and an objective response rate of about 35% in patients evaluated for their response.
What is the significance of Cyclin E1 in PROC patients?
Cyclin E1 serves as a predictive biomarker, helping identify patients who are more likely to benefit from treatment with azenosertib.
When will Zentalis initiate Part 2 of the DENALI trial?
Zentalis plans to initiate enrollment for Part 2 of the DENALI trial in the first half of 2025.
What adverse effects were noted during the trials?
Common adverse effects reported included gastrointestinal issues and fatigue, which were consistent with previous data presentations.
